Research Looks to Reduce Side Effects in Commonly Used Drugs
News Feb 28, 2018 | Original story from The Australian National University (ANU)
New research from The Australian National University (ANU) has drilled down to the molecular level to find similarities across six pharmaceutical drugs used in pain relief, dentist anaesthetic, and treatment of epilepsy, in a bid to find a way to reduce unwanted side-effects.
One in five Australians experience chronic pain, and 250,000 Australians live with epilepsy, 40 per cent of which are children.
Until now, researchers have known that drugs which treat pain and epilepsy are effective, some of which have even been used clinically since the 1950s. But molecular details of how they work and why they cause side effects have not been studied until relatively recently, thanks to new technology.
Dr Amanda Buyan from the ANU Research School of Biology said thanks to the National Computational Infrastructure (NCI) super computing power at ANU, researchers are now able to run bigger and more complex simulations to get a better picture of what is going on.
"Understanding the molecular detail of how they work gives us clues to why these drugs might be effecting one part of the body that we want, but may also effect part of the body that we don't want to effect," she said.
"Understanding this can hopefully inform future scientists working on drug discovery that this is how we think these types of drugs work."
Dr Buyan hopes the research will better inform scientists about the possibility of changing the structure of existing drugs, or in designing a new drug to make sure that it does what is intended without the side effects.
"I hope that it leads to drugs being changed slightly to be more specific or lead to a different avenue that might be more fruitful."
This article has been republished from materials provided by The Australian National University (ANU). Note: material may have been edited for length and content. For further information, please contact the cited source.
Resistance to Antifungals Could Lead to Disease and Global Food ShortagesNews
Growing levels of resistance to antifungal treatments could lead to increased disease outbreaks and affect food security around the world.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.